One thing that concerns me a little if ABBV's cocktail sells well is disagreement over royalties. determining the contribution of the various components is not cut and dry (of course i am not privy to the fine print of the agreement) if i recall abbott contested royalty on humira quite vigorously with CAT - and that agreement was probably simpler in structure than the one with ENTA
Market Data 
Markets 
AI
